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Background: Pseudoxanthoma elasticum (PXE) is characterized by skin (papular lesions), ocular (subretinal
neovascularisation) and cardiovascular manifestations (peripheral artery disease), due to mineralization and
fragmentation of elastic fibres in the extracellular matrix (ECM). Caused by mutations in the ABCC6 gene, the
mechanisms underlying this disease remain unknown. The knowledge on the molecular background of soft tissue
mineralization largely comes from insights in vascular calcification, with involvement of the osteoinductive
Transforming Growth Factor beta (TGFβ) family (TGFβ1-3 and Bone Morphogenetic Proteins [BMP]), together with
ectonucleotides (ENPP1), Wnt signalling and a variety of local and systemic calcification inhibitors. In this study, we
have investigated the relevance of the signalling pathways described in vascular soft tissue mineralization in the
PXE knock-out mouse model and in PXE patients.
Methods: The role of the pro-osteogenic pathways BMP2-SMADs-RUNX2, TGFβ-SMAD2/3 and Wnt-MSX2, apoptosis
and ER stress was evaluated using immunohistochemistry, mRNA expression profiling and immune-co-staining in
dermal tissues and fibroblast cultures of PXE patients and the eyes and whiskers of the PXE knock-out mouse.
Apoptosis was further evaluated by TUNEL staining and siRNA mediated gene knockdown. ALPL activity in PXE
fibroblasts was studied using ALPL stains.
Results: We demonstrate the upregulation of the BMP2-SMADs-RUNX2 and TGFβ-2-SMAD2/3 pathway,
co-localizing with the mineralization sites, and the involvement of MSX2-canonical Wnt signalling. Further, we show
that apoptosis is also involved in PXE with activation of Caspases and BCL-2. In contrast to vascular calcification,
neither the other BMPs and TGFβs nor endoplasmic reticulum stress pathways seem to be perturbed in PXE.
Conclusions: Our study shows that we cannot simply extrapolate knowledge on cell signalling in vascular soft
tissue calcification to a multisystem ectopic mineralisation disease as PXE. Contrary, we demonstrate a specific set of
perturbed signalling pathways in PXE patients and the knock-out mouse model. Based on our findings and
previously reported data, we propose a preliminary cell model of ECM calcification in PXE.
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Pseudoxanthoma elasticum (PXE; OMIM # 264800) is an
autosomal recessive systemic connective tissue disease af-
fecting the extracellular matrix (ECM) of multiple organs
[1]. It is characterized by dermal (papular lesions in flexural
areas), ocular (angioid streaks, subretinal neovascularisation
and haemorrhage) and vascular symptoms (coronary
and peripheral vascular disease) which result from
mineralization and fragmentation of elastic fibres. PXE is
caused by mutations in the ABCC6 (ATP-binding cassette
subfamily C member 6) gene, encoding a transmembrane
ATP driven organic anion transporter, the substrate of
which is currently unknown. The biological mechanisms of
ectopic mineralization in PXE, including the exact relation-
ship with the defective ABCC6 transporter remain unclear
[2]. Current knowledge on the molecular background of
soft tissue mineralization largely comes from insights in
vascular calcification (Figure 1). Murine models of calcified
vasculopathies demonstrate that signalling pathways in-
volved are those required for the physiological development
of bone and cartilage, influencing gene transcription, apop-
tosis, matrix vesicle formation, endoplasmic and oxidative
stress. Main protagonists are the osteoinductive Transform-
ing Growth Factor beta (TGFβ) family (TGFβ1-3 and Bone
Morphogenetic Proteins [BMP]), together with ectonucleo-
tides (ENPP1), Wnt signalling and a variety of local and sys-
temic calcification inhibitors, many of which have been
previously associated with PXE, such as matrix Gla protein
(MGP), osteocalcin (OC), bone sialoprotein (BSP or osteo-
pontin), osteoprotegerin (OPG) and fetuin-A [3-9]. MGP is
a protein belonging to the family of so-called “gla-proteins”,
because of the presence of “gla-residues” which need to
undergo gamma-carboxylation for activation of the pro-
tein. This carboxylation process is performed by the
GGCX (gamma-glutamylcarboxylase) enzyme in the so-
called ‘vitamin K (VK)-cycle’, as VK is an essential co-
factor for this post-translational modification [10]. MGP
serves as mineralization inhibitor via direct repression
of bone morphogenetic protein-2 (BMP2), an osteo-
inductive member of the TGF-β family of growth factors
[11-13], which has also been implicated in directing soft
tissue calcification [14]. We and others have previously
shown that MGP is abundantly present in calcified PXE tis-
sues in its uncarboxylated or inactive form and that the loss
of MGP repression on BMP2 results in an upregulation of
BMP2 in the middermis of PXE patients [5]. The observa-
tion of low VK1 serum levels in PXE patients was suggested
as a contributing factor leading to this inefficient carboxyl-
ation of MGP. Besides local inhibitors, PXE patients
were shown to have a deficiency of the systemic
mineralization antagonist Fetuin-A [15]. Recently, the
role of the ectonucleotide pyrophosphatase/phospho-
diesterase 1 or ENPP1 was confirmed as mutations in
the encoding gene can also result in PXE [16,17].However, limited information is available on the key
cellular pathways of soft tissue mineralization, the TGFβ
superfamily-related signalling - its ligands (TGFβ1-3,
BMPs), its receptors (TGFβR1/2, BMPRI/II) and its intra-
cellular signal transducers (SMADs - Mothers Against Dec-
apentaplegic homolog proteins) -, Wnt signalling, apoptosis
or ER stress, in PXE. In the heart of Abcc6 −/−mice, the
BMP responsive transcription factors Smad1/5/8 were
found to be upregulated, implying deregulation of BMP sig-
nalling pathways. Though no other tissues were examined,
the authors concluded that further study of the BMP signal-
ling axis may be of importance in the study of PXE [37].
The potential importance of these signalling pathways was
recently endorsed by Sowa et al. demonstrating ectopic ex-
pression of RUNX2 in calcified cardiac tissue of the Dys-
calc1 mice, in which an Abcc6 splice variant results in
Abcc6 transporter deficiency [38]. These findings suggest
that signalling pathways implicated in calcified vasculopa-
thies may be relevant for PXE, though it may seem pre-
sumptuous to assume that their involvement is identical in
a complex multisystem calcification disease such as PXE. In
this study, we have investigated the relevance of the
signalling pathways described in vascular soft tissue
mineralization in the PXE knock-out mouse model and in
PXE patients. We demonstrate perturbance of several but
not all effectors of vascular mineralization. We have com-
bined our results and literature data on PXE to propose a
preliminary cell-based model of ECM mineralization in
PXE as a starting point for cellular research in this complex
disease.Methods
Ethics statement
This study was approved by the Ethical Committee of
the Ghent University Hospital. Informed consent was
obtained from all patients and the Declaration of
Helsinki protocols were followed.Abcc6 KO mice
The mouse model for PXE has been developed by targeted
ablation of the Abcc6 gene [39]. The mice were maintained
in the Animal facility of the Department of Cell and
Molecular Biology, John A. Burns School of Medicine, Uni-
versity of Hawai’i. These knockout mice recapitulate the
histopathological and ultrastructural features of human
PXE. In addition, a prominent mineralization of the con-
nective tissue capsule surrounding the hair follicles in vibris-
sae of this mouse model has been observed. This feature has
been proposed as an early biomarker of the overall
mineralization process in PXE [9]. The IHC experiments in
this study were performed on paraffin embedded tissues
of the eyes (Bruch’s membrane) and whiskers of the
Abcc6 −/−mice.
Figure 1 Schematic representation of the pathways (1–10) involved in vascular soft tissue mineralization. Vascular calcification is the result of a
transdifferentiation process of vascular smooth muscle cells (VSMCs) to chondrocyte-like or osteoblast-like cells [18]. (1) BMP2 and BMP4 induce osteogenic
differentiation through SMAD dependent signal transduction. BMP2/4 ligands bind with BMP receptors BMPR-I and BMPR-II; BMPR-II then phosphorylates
and activates BMPR-I. Phosphorylated BMPR-I subsequently phosphorylates SMAD1, SMAD5 and SMAD8 (SMAD1, 5, 8) which associate with SMAD4 to
form the heteromeric pSMAD1,4,5,8. This facilitates nucleation, where they regulate the pro-osteogenic runt-related transcription factor RUNX2 [19].
Downstream targets of RUNX2 include osterix (OSX), alkaline phosphatase (ALPL or TNAP), osteopontin (OPN), osteocalcin (OC) and collagen type-1 (Col-1)
[20]. (2) TGF-βs (1-2-3) bind to TGF-β receptor type I or II, resulting in phosphorylation of SMAD2/3, coupling with SMAD4 and translocation into the
nucleus [21-23], where they trigger targeted gene expression of connective tissue growth factor (CTGF) [24-26]. (3) BMP7 activates endogenous SMAD1,5,8
and forms a SMAD1,4,5,8 complex, facilitating nucleation and stimulation of VSMC specific genes (SM-MHC, SM actin, MGP, Id-2). Through SMAD6 and
SMAD7, BMP7 also inhibits BMP2 and TGF-β signalling [27]. (4) Elevated inorganic phosphate (Pi) enters the cell via sodium-dependent phosphate
co-transporters PiT-1 and 2, resulting in downregulation of mineralization inhibitors, apoptosis (through downregulation of GAS6 and BCL-2, thus activating
caspases), and upregulation of RUNX2 through ERK1/2 activation [28-30]. (5) MSX2 upregulates different Wnt receptors, causing stabilization of β-catenin,
which after nucleation increases TCF-1/LEF-1 dependent gene expression. This in turn can upregulate MSX2 expression [31]. (6) DLX5 drives RUNX2
expression and osteogenic differentiation, and can abrogate osterix induction by BMP2. DLX5 also negatively regulates the activity of MSX2 [32]. (7) ER
stress initiates a cascade of chaperone proteins leading to activation of caspases such as Caspase 12 and apoptosis (so-called unfolded protein response)
[33]. (8) BMP2 can directly increase expression of ERK1/2, thus increasing RUNX2 expression and SMC phenotypic transition toward osteochondro-
progenitors [34]. (9) Oxidative stress and inflammatory mediators respond with higher BMP2/4 secretion in VSMCs calcification process [35,36]. (10) Tissue
nonspecific alkaline phosphatase (TNAP or ALPL) has a major role both as a PPiase and as an ATPase/ADPase and thus participates in the calcification
process by restricting the concentration of extracellular PPi, a calcification inhibitor. Nucleotide pyrophosphatase phosphodiesterase 1 (NPP1) works as a
backup for PPiase and ATPase, especially in the absence of [27].
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Dermal tissues and fibroblast cultures were obtained
through full thickness skin biopsies in macroscopic skin
lesions from clinically and molecularly confirmed PXEpatients followed in the PXE Clinic of the Ghent Center
for Medical Genetics.
Fibroblasts of 8 PXE patients and 5 healthy age- and sex-
matched controls were cultured in Dulbecco’s modified
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1% penicillin/Streptomycin, 1% Kanamycin, 1% non-
essential amino acid and 0.1% fungizone. Cultures were
maintained by refreshing media twice a week and incubated
at 37°C (5% CO2). First, fibroblasts were grown in T25 cm
2
flask; when 100% confluent, fibroblasts were spliced and
transferred in T75 cm2 flask. When 100% confluent, cells
were spliced and grown in 60 mm petri-dishes. Fully con-
fluent 60 mm petri-dishes were scraped and centrifuged to
extract the tissues and stored at −80°C.
Histological analysis
Alizarin red staining (ARS): Five μm sections from
muzzle skin containing whiskers (or vibrissae) from
Abcc6−/−mice and lesional skin sections from PXE
patients were stained with 2% (pH 4.2, freshly prepared)
ARS (Sigma-Aldrich, Belgium). To observe ARS in fibro-
blast cultures (n = 3), cells were fixed in 10% phosphate-
buffered formalin, subsequently washed with PBS
(pH 7.4) and stained with Alizarin Red solution
(40 mM Alizarin Red-Tris–HCl, pH 4.1) at room tem-
perature (RT) for 10 min. After washing three times with
PBS, cells were mounted with vectashield (Vectastain kit,
Labconsult, CA).
Alkaline phosphatase (ALPL) staining: To detect ALPL
activity, control (n = 3) and PXE (n = 3) fibroblasts were
cultured in an 8 well chamber slide, fixed with 0.4% cold
paraformaldehyde (10 min.), rinsed with ALPL solution
(100 mM Tris–HCl, pH 9.5, 100 mM NaCl, 10 mM
MgCl2) and stained with a 1% BM Purple solution
(Roche Molecular Biochemicals, Belgium) at 37°C
(30 min.). After light microscopical evaluation (Zeiss,
Germany), images were taken for all experiments using
Axiovision Reflected Light 4.6 software (Carl Zeiss
MicroImaging, GmbH, Germany).
Immunohistological analysis
Immunohistochemistry (IHC) was performed on
formalin-fixed and paraffin embedded whisker and eye
tissues (5 μm) of Abcc6 KO mice and human dermal tis-
sues prepared from lesional skin biopsies, using primary
antibodies against BMP2 (Abcam, USA), pSMAD1
(Abcam, USA), pSMAD2 (Cell Signalling Technology,
The Netherlands), pSMAD4, 5 (Abcam, USA) and
pSMAD8 (Santa Cruz Biotechnology, Inc., Germany),
pSMAD1-5-8 (an antibody recognizing SMAD1 only
when dually phosphorylated at Ser463 and Ser465, as
well as phosphorylated SMAD5 and SMAD8; Abcam,
USA), RUNX2 (M70, Santa Cruz Biotechnology, Inc.,
Germany), CTGF (Abcam, UK), Caspase 3 (BIOKE, Cell
Signalling Technology, The Netherlands) and pERK1/2
(Abcam, UK). Labelling was always performed on slides
adjacent to those with proven mineralization on Alizarin
Red staining (Sigma-Aldrich, Belgium). Each labellingwas done on 5 (patients, mouse tissues) or 3 (human
controls) slides. Briefly, antigens were unmasked after
deparaffinization, using 1 mM EDTA (pH 8, boiled for
20 min.), cooled down (30 min. at RT) and subsequently
antibody binding steps were performed by washing sec-
tions in distilled water (3 × 5 min.), 3% hydrogen pero-
xide (1 × 10 min.), distilled water (2 × 5 min.) and in
TBS-T (1 × 5 min.). Sections were blocked with 5% BSA
(in TBST) for 1 h. at RT. After removal, sections were
incubated with primary antibodies (1:100 dilution in
TBST + 5% Bovine Serum Albumin) overnight at 4°C in
a moist chamber. After washing, the secondary antibody
(Rabbit IgG) was added according to manufacturer’s re-
commendation (Vectastain kit, Labconsult, CA). After
washing, tissue sections were incubated with ABC re-
agent (45 min. at RT; Vectastain kit, Labconsult, CA)
and subsequently treated with AEC reagent (30 min.) or
DAB (Vectastain kit, Labconsult, CA). Slides were washed
mounted with cover slips. Tissue sections were evaluated
using light microscopy (Zeiss, Germany). Images were
taken using Axiovision Reflected Light 4.6 software (Carl
Zeiss Microlmaging, GmbH, Germany).
Fluorescent immunohistochemistry
To detect co-localization of RUNX2-Caspase 8, fluores-
cent immunohistochemistry was performed on PXE skin
tissue (n = 5). Tissue sections were deparaffinized, and
blocked with 5% BSA (1 h), incubated with an anti-
rabbit polyclonal RUNX2 antibody (1:200; M 70, Santa
Cruz Biotechnology Inc., Germany) and an anti-mouse
monoclonal Caspase 8 antibody (1:200; BIOKE, Cell Sig-
nalling Technology, The Netherlands) for 2 hrs. After re-
moval of the primary antibody, the sections were
incubated with the secondary antibody Cy3 (anti-rabbit,
1:100; GE Healthcare, Germany) and Alupa 488 (anti
mouse, 1:100; Life Technologies Europe) for 1 h.
All tissues were mounted with vectashield with DAPI
(Vectastain kit, Labconsult, CA) and images were taken
under the fluorescent microscope (Axioplan 2 Imaging,
Zeiss, Germany).
Gene expression quantification by qPCR
qPCR analysis was performed for key genes involved in
the BMP2/BMP4-SMADs-RUNX2 signalling pathway
(RUNX2, BMP2, BMP4, SMAD1, SMAD4, SMAD5,
SMAD8), the downstream RUNX2 target gene Osterix and
ALPL, genes in the TGFβ signalling pathway (TGFβ-1,
TGFβ-2, TGFβ-3, SMAD2, SMAD3 and CTGF), genes of
the MSX2-Wnt pathway (MSX2, DLX5, LEF-1, TCF-1 and
β-catenin), the inorganic phosphate transporter PiT-1,
genes involved in apoptosis pathways (P21, GAS6, BCL-2,
Caspase3), and genes for endoplasmic reticulum stress
(CHOP, BIP, XBP1, IRE1, ATF4, ATF6, GAD34, JNK, XBP-
S). RNA was isolated from fully confluent fibroblasts using
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manufacturer’s recommendation. To purify the RNA from
any DNA that may be present, it was incubated with DNase
(15 min. at RT). Concentration of total RNA was measured
via the DropSense-96 multichannel spectrophotometer
(Micronic North America, USA). cDNA was prepared from
2 μg of RNA using the iScript cDNA synthesis kit (Bio-Rad
Laboratories, CA) and diluted 10-fold. qPCR was
performed on control (n = 5) and PXE fibroblasts (n = 8)
using HPRT1 (hypoxanthine phosphoribosyl transferase 1)
and YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta isoform) as refer-
ence genes and the FastStart Universal Probe Maser Mix
(Roche Applied Science, GmbH, Germany) in the Roche-
LightCycler®480 real-time PCR system (Roche Applied Sci-
ence, Belgium). qPCR primers are listed in Additional file 1:
Table S1. Real time PCR data were analysed via the qbase-
PLUS software (Biogazelle, Belgium).
In situ cell death detection
In vitro evaluation of fibroblast cell death was performed
via the in situ cell death detection (TUNEL - Tdt-mediated
dUTP Nick-End Labelling) kit (Roche Diagnostics, GmbH,
Germany). PXE fibroblasts were grown in 75 cm2 flask
until 100% confluent. Concentration of the cells/ml was
determined using an automated cell counting machine
(Cellometer®auto T4, Nexcelom Bioscience, USA). Forty
thousand cells per well were distributed on an 8 well plate.
After 2 days, cells were washed with PBS (pH 7.4). Cells
were stained with the TUNEL kit according to the manu-
facturer’s protocol after 24, 72 and 120 hrs. respectively.
Percentage of cell death was counted under fluorescent
microscope (Axioplan 2 imaging, Zeiss, Germany). For each
cell culture (n = 6 for patients and 5 for controls), 10 micro-
scopic fields were evaluated.
RUNX2 siRNA transfection
To evaluate the expression of RUNX2 at different time
points (24, 48 and 72 hrs.) after siRNA transfection, 2 × 105
PXE fibroblasts (n = 6 cultures) were seeded in 6 well
plates. After 24 hrs. cells were transfected with 6 μl (2 μM)
of RUNX2 siRNA (sc-37145, sc-36868, sc-29528, Santa
Cruz Biotechnology, Inc, Europe) or scrambled RNA (sc-
37007, Santa Cruz Biotechnology, Inc, Europe) according
to the manufacturer’s recommendations. Expression of
RUNX2 after siRNA transfection was evaluated by qPCR
(using primer sc-37145-PR, Santa Cruz Biotechnology, Inc,
Europe) after 24, 48 and 72 hrs. (n = 2 cultures) TUNEL
assay was performed as described above, respectively at 24,
48 and 72 hrs. after siRNA transfection (n = 6 cultures).
Statistical analysis
All data were analysed using the statistical software S-
PLUS 8 (Insightful, Washington). Normality distributionof the data was evaluated by the Kolmogorov-Smirnov
test. Differences between groups were compared using
the one-sample t-test. Significance was considered at a
confidence level of 0.95 and p < 0.05.Results
The BMP2-SMADs-RUNX2 pathway is upregulated in
human and murine PXE
One of the most important pathways in vascular calcifica-
tion involves BMP2-SMADs-RUNX2 signalling, as RUNX2
is considered a master regulator of mineralization. To study
the relevance of this pathway in PXE, first IHC staining of
key proteins of this pathway was performed on the vibrissae
and eyes of the Abcc6 KO mouse. Labelling for BMP2,
pSMAD1, pSMAD4, pSMAD5, pSMAD8, pSMAD1-5-8
and RUNX2 revealed increased expression in the connect-
ive tissue capsule around the whiskers and in Bruch’s mem-
brane of the eye compared to the wild type. These
labellings co-localized with mineralization foci as seen on
Alizarin Red stains (Figure 2). Subsequently, identical IHC
stains were performed on human PXE dermis, which re-
vealed identical results for all proteins. Positive staining in
the human samples was confined to the mid-dermal skin
area of elastic fibre mineralization compared to no staining
in controls (Figure 3, A-G).
qPCR experiments performed for RUNX2, BMP2,
BMP4, SMAD1, SMAD4, SMAD5, SMAD8, Osterix and
ALPL confirmed a significant upregulation of RUNX2,
BMP2, SMAD1, SMAD4, SMAD5, SMAD8 and ALPL
in PXE fibroblasts compare to healthy controls (Figure 4),
whereas expression of BMP4 and Osterix remained same
as control. ALPL, one of the target genes of RUNX2, en-
codes the enzyme alkaline phosphatase (ALPL) which is
an inducer of mineralization and showed the highest up-
regulation compared to controls (more than 3-fold; p <
0.05), whereas RUNX2 showed a more than 2-fold in-
crease in expression (p < 0.05). The ALPL upregulation
was also demonstrated on fibroblast cultures of PXE pa-
tients, where staining for Alizarin Red and ALPL showed
positive labelling for both in PXE cells compared to con-
trols (Figure 3, H-M).MSX2 expression is influenced by increased BMP2 and
activates LEF-1/TCF-1 transcription
Besides SMADs-RUNX2 signalling, BMP2 can also upregu-
late MSX2. The expression of MSX2 was indeed signifi-
cantly upregulated in PXE fibroblast compared to health
controls (Figure 5). This was further corroborated by a de-
creased DLX5 expression, a known repressor of MSX2. In
vascular calcification, MSX2 overexpression stimulates nu-
clear localisation of β-catenin, thus activating transcription
of LEF-1 and TCF-1. Indeed, qPCR experiments reveal that
expression of LEF-1 and TCF-1 was upregulated in PXE
Figure 2 Staining results for the BMP2-SMADs-RUNX2 pathway in whisker and eye sections from the Abcc6 KO mouse (×10). Negative
controls are shown in the first column (A, E, I, M, Q, U, Y). Alizarin Red stainings confirms profound calcification in the connective tissue capsule
of the whiskers (B, F, N, R, V and Z) and Bruch’s membrane of the eye (J). Immunohistochemical staining of adjacent slides with antibodies
against respectively Bmp2 (C), Runx2 (G, K), pSmad4 (O), pSmad5 (S), pSmad8 (W) and pSmad1/5/8 (Aa), shows positive staining for all,
co-localizing with the mineralization foci. Arrowed areas of positive staining have been magnified (×20). Scale bar = 100 μm. n = 5 each.
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Figure 3 Immunohistochemical labelling results of the SMAD-
RUNX2 pathway in human PXE skin (n = 5 each) and fibroblasts
(n = 8 each) compared to controls (n = 3 each) (×10). The top-left
panel shows absence of staining in controls (A), positive middermal
staining for Alizarin red (B) and RUNX2 (C) in PXE skin. The top-right
and middle two panels (D to H) depicts staining for pSmad4 (D),
pSmad5 (E), pSmad8 (F) and pSMAD1/5/8 (G) with positive labelling
in the middermis of PXE patients compare to no labelling in the
negative controls (inserts). The lower panel reveals positive labelling
for Alizarin Red (J, K) and ALPL (L, M) in PXE fibroblast cultures (n =
3) compared to controls (n = 3) (I, L). Areas marked with asterisk are
enlarged (×40). Scale bar = 100 μm.
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expressed within normal limits (Figure 5).
Human and murine PXE manifest increased TGFβ-2
signalling
qPCR expression analysis of the three ligands of the TGFβ
family - TGFβ-1, TGFβ-2, TGFβ-3 - demonstrated in-
creased expression of only TGFβ-2, while the others were
within normal limits (Figure 6). After binding to a type II
receptor dimer, TGFβ-2 is mediated by pSMAD2/3 and
CTGF. To further confirm increased activity of TGFβ-2,
qPCR of the critical downstream SMAD2, SMAD3 and
CTGF gene in human PXE fibroblasts, and immunohisto-
chemistry of critical mediators on murine and PXE tissues
were performed. These experiments confirmed in-
creased expression of the TGFβ-2 downstream signal-
ling mediator CTGF (Figure 6). The expression of
SMAD2 and SMAD3 was not significantly different
compared to controls (Figure 6). Positive staining, co-
localizing with mineralization, of pSMAD2 and CTGF
was demonstrated in the PXE middermis (Figure 7, G-I
and M-O respectively), and only pSMAD2 but not
CTGF in the vibrissae and eye of the PXE KO mouse,
compared to absent staining in controls (Figure 7, A-F
and J-L respectively).
Increased apoptosis in PXE tissues is only partially
mediated by RUNX2
Apoptosis is considered an important mechanism in soft
tissue mineralization. We evaluated the presence of apop-
tosis in PXE fibroblast cultures using a TUNEL assay, light
and fluorescent IHC. DAPI staining revealed the nuclear
diameter to be smaller in PXE fibroblasts compared to con-
trols (Figure 8). After 72 hrs., TUNEL staining showed 3×
more apoptosis compared to controls (2.08% and 0.69% re-
spectively, p < 0.05) (Figure 8; Additional file 2: Figure S2).
This staining did not always co-localize with the nuclear
DAPI labelling, but was present in the cytoplasm of the
cells (Figure 8; Additional file 3: Figure S3). Caspase 3 and
Caspase 8 - both critical executioners of apoptosis -, were
used as biomarkers for immunohistochemical evaluation of
apoptosis [40]. IHC labelling of caspase 3 on murine
Figure 4 Relative expression of components of BMP2-SMADs-RUNX2 signalling including RUNX2, BMP2, BMP4, SMAD1, SMAD4,
SMAD5, SMAD8, Osterix, and Alkaline Phosphatase (ALPL). Relative expression is shown in human PXE fibroblasts and control cells. A
significant upregulation of all genes except BMP4 and Osterix was observed compared to controls. (n = 8 and 5 for patients and controls
respectively). *p < 0.05.
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mineralization foci (Figure 9, A-D).
Several signal transduction components have been attrib-
uted pro-apoptotic properties. RUNX2, P21, GAS6/BCL-2
and PiT-1 have all been involved in apoptosis-induced vas-
cular calcification. Besides the upregulation of RUNX2 and
GAS6, and downregulation of BCL-2, none of other media-
tors were found to show a significantly different expression
pattern in PXE fibroblasts compared to controls (Figure 10).
As also the Unfolded Protein Response (UPR), a cellular
stress response originating from the ER, was shown to initi-
ate apoptosis in vascular mineralization by inducing cas-
pases, we evaluated several ER stress markers (CHOP, BIP,
XBP1, IRE1, ATF4, ATF6, GAD34, JNK, XBP-S) in PXE fi-
broblasts but found none to be significantly different com-
pared to healthy controls (Figure 11).
As RUNX2 was differentially expressed in PXE and to
confirm its presence in the foci of apoptosis, we performedFigure 5 Relative expression of mediators in MSX2-Wnt signalling (M
upregulation of MSX2, LEF-1 and TCF-1 as well as significant downregulatio
β-catenin is not differentially expressed in PXE fibroblasts. (n = 8 and 5 for pfluorescent IHC co-labelling with Caspase 8, confirming
co-localisation of both antibodies (Figure 9, G-J). To further
evaluate the contribution of RUNX2 to apoptosis, a siRNA
experiment was performed to knock-down RUNX2 expres-
sion. Expression levels were downregulated by 67% after
24 hrs., diminishing to 51% and 31% after 48 and 72 hrs. re-
spectively compared to cells treated with siRNA and un-
treated cells (Additional file 4: Figure S4). As TUNEL
staining for apoptosis in PXE fibroblasts tends to have the
highest yield after 72 hours, we mainly focused at the 48 h.
time frame where there was still more than 50% downregu-
lation of RUNX2. TUNEL staining on siRNA transfected fi-
broblasts showed a visual decrease of apoptosis after 24
and 48 hrs., which could not be seen anymore after 72 hrs.
(Figure 8). Quantification of apoptosis in the transfected fi-
broblasts showed a reduction of 13 to 20% in the first 24 to
48 hrs., but with variable results between cell cultures
(Additional file 5: Figure S5).SX2, DLX5, LEF-1, TCF-1 and β-catenin). qPCR reveals a marked
n of DLX5 in human PXE fibroblasts compared to control cells.
atients and controls respectively). *p < 0.05.
Figure 6 qPCR result for markers involved in TGFβ signalling pathway (TGFβ-1, TGFβ-2, TGFβ-3, SMAD2, SMAD3 and CTGF). While
relative expression of TGFβ-1 and −3 are normal, upregulation of TGFβ-2 and CTGF can be seen in human PXE fibroblasts compared to control
cells. (n = 8 and 5 for patients and controls respectively). *p < 0.05.
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http://www.ojrd.com/content/9/1/66pERK1/2 activation in PXE may be due to BMP2 effect
RUNX2-dependent transcription can also be regulated
through the MEK/ERK pathway, either via BMP2 and/or
PiT-1. We observed upregulation of pERK1/2, co-
localizing with the calcified regions of both human PXE
skin (middermis) and murine whiskers (Figure 12). PIT-
1 expression was within normal limits (Figure 10).
Discussion
Soft tissue mineralization is a complex process resulting
from perturbation of a delicate interplay of developmen-
tal cues, protein signalling, transcription factors and
their regulators. It is involved in both orphan and com-
mon disorders, leading to significant morbidity and mor-
tality. Though still incompletely understood, important
progress has been made in unravelling the signal trans-
duction pathways leading to ectopic calcification. For
this, vascular calcification has often been used as a
model, in which the knowledge of cellular signalling re-
sulted in improved understanding of the disease and
novel therapeutic approaches [41,42]. Among orphan
diseases, pseudoxanthoma elasticum is often considered
a paradigm for ectopic mineralization disorders [43].
The pathophysiology of elastic fibre mineralization in
PXE has so far remained unclear, though several mecha-
nisms have been suggested to be involved, including
chronic oxidative stress, an unidentified serum factor
and deficiency of circulatory and local mineralization in-
hibitors [5,44]. Thus far, the data on cellular events in
PXE are limited, restricted to specific tissues such as the
heart and performed only in animal models [45]. It is
unclear if and to what extent cellular mechanisms in-
volved in vascular calcification are relevant in a multisys-
tem mineralization disease such as PXE and more
specifically in PXE patients. As it was recently demon-
strated that these patients present a rather specificvasculopathy, differing from age-related atherosclerosis,
it would seem presumptuous to automatically extrapo-
late the knowledge of calcified vasculopathies to PXE
[16,46]. The pathobiological mechanisms in vascular cal-
cification can be divided into two broad categories:
induction of osteogenesis and loss of inhibitors of
mineralization. Previous studies have already shown that
several local and systemic calcification inhibitors, such
as MGP and Fetuin-A, are functioning inadequately in
PXE [5,15]. For the induction of an osteochondrogenic
phenotype, the contribution of TGFβ signalling, BMPs-
SMADs-RUNX2 signalling, Wnt-MSX2 signalling, apop-
tosis, oxidative stress and ER stress are well appreciated
in calcified vasculopathies [3-9]. In this study, we wanted
to assess which of these signalling pathways, if any, are
perturbed in the PXE murine model and in PXE
patients.
The TGFβ superfamily consists of a large number of
members (TGFβs, activins, inhibins, nodals, anti-mullerian
hormone and BMPs) involved in various biological pro-
cesses such as cell proliferation, differentiation, migration,
adhesion, apoptosis and ECM production [47,48]. In ec-
topic mineralization, particularly BMPs and TGFβs have
been attributed a prominent role [49]. BMP2 and BMP4
are important propagators of ectopic mineralization in ves-
sels through a concerted action with SMADs, and down-
stream key osteogenic transcription factors including
RUNX2 (or Cbfa1), MSX2 and osterix (OSX) [40,50,51].
They can induce osteoblast differentiation in a variety of
vascular cells [49]. BMP7 has been shown to inhibit
vascular calcification [52]. Although Mungrue et al. de-
scribed an upregulation of BMP4 in cardiac tissue of
the Abcc6−/−mouse [37], we could not confirm in-
volvement of BMP4 in PXE, though a tissue-specific ef-
fect cannot be fully excluded [53]. Comparably, BMP7
activity was also within normal limits in PXE, but
Figure 7 Immunohistochemical labelling of key mediators of TGFβ-2 signalling in whisker and eye sections from the abcc6 knockout
mouse (and skin tissues from PXE patients (×10). Alizarin Red staining visualizes calcification in the whiskers (A, J), Bruch’s membrane of the
eye (D) and mid-dermis of the skin tissues (G, M). Immunohistochemical staining of adjacent slides with antibodies against pSMAD2 (B, E, H,
arrowed) and CTGF (N, asterisk), show positive staining, co-localizing with the mineralization foci. In the whisker sections of the mouse model, no
CTGF staining could be observed (K). Staining of wild-type whisker (C, L), eye (F), and human skin tissues (I and O) did not show any staining.
(n = 5 each). Scale bar = 100 μm.
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and Bruch’s membrane of Abcc6 KO mice as well as in
the mid-dermis and fibroblasts of PXE patients, co-
localizing with the elastic fibre mineralization. BMP2
activity is regulated by MGP, which in its active,carboxylated form can prevent BMP2 to interact with
its receptor [54]. The excess of uncarboxylated MGP in
PXE may thus contribute to the upregulation of BMP2,
though it is not excluded that other mechanisms, such
as epigenetic changes, are also involved [20].
Figure 8 Analysis of apoptosis by TUNEL staining in human fibroblasts (n = 6) compared to control cells (n = 5) (×20). Counter staining
was performed using DAPI nuclear staining and pictures were taken using DAPI (upper row), FITC (fluorescein isothiocyanate; middle row) and
Merged (lower row) filters. Results are shown for a positive and negative control (A, B), healthy control fibroblasts (C), PXE fibroblasts (D) and PXE
fibroblasts transfected with RUNX2 siRNA respectively 24 (E), 48 (F) and 72 hours (G) following transfection. PXE fibroblasts show smaller nuclei
on the DAPI stain and increased TUNEL staining in the cytoplasm of fibroblasts compared to controls, reflecting a three-fold increase of apoptosis
(2,08% vs 0.69% respectively, p < 0.05). Twenty-four and 48 hours post-transfection with RUNX2 siRNA, a decrease of apoptosis can be seen,
whereas after 72 hours no difference can be observed compared to untreated PXE fibroblasts. Scale bar = 20 μm.
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http://www.ojrd.com/content/9/1/66Though BMP2 is a crucial mediator of vascular calcifi-
cation, its downstream affects are achieved through the
upregulation of RUNX2, MSX2 and OSX [49-51]. In-
creased immunostaining of pSmad1, pSmad4, PSmad5,
pSmad8 and pSmad1-5-8 and RUNX2 in PXE and
Abcc6−/−murine tissues confirms that in PXE a coordi-
nated activation of the BMP2- SMADs-RUNX2 signal-
ling pathway occurs. RUNX2 is considered the master
regulator of osteogenesis, although the gene is not
osteoblast-specific [53]. Its upregulation has been
observed in calcified vasculopathies, together with
MSX2 and OSX, confirming its role in soft tissue
mineralization, where it induces VSMC to acquire an
osteogenic phenotype [20,54-56]. This osteogenic differ-
entiation is obtained through induction of ALPL activity
and expression of bone matrix protein genes OC, Col 1,
and BSP [54,57]. Similar changes could be seen in PXE
fibroblasts, with increased ALPL expression on qPCR
and increased ALPL activity in human cultured fibro-
blasts. ALPL promotor activity may also be stimulated in
a RUNX2-independent manner by DLX5 (Distal-less
homeobox 5), but little DLX5 activity could be seen in
PXE cells excluding this regulatory mechanism [58]. The
mRNA expression of ALPL being considered a reliable
method to determine BMP2-induced osteogenic differ-
entiation of cells, this suggests that PXE fibroblastsadopt a gene expression profile similar to osteoblasts. It
is also known that other target genes of RUNX2, such as
OC or BSP, are abundantly present in PXE tissues [5,8].
Interestingly, RUNX2 has a dual effect on BSP. While
normally inducing an overt BSP overexpression, RUNX2
has a tendency to decrease this BSP expression when
upregulated itself. This might explain the observation of
Contri et al. that BSP, though present, was significantly
less abundant in PXE tissues compared to other pro-
mineralizing proteins [21].
Besides induction by BMP2-SMADs, RUNX2-dependent
transcription can also be regulated through the MEK/ERK
(Extracellular Signal Regulated Kinases) pathway [59]. In
vascular calcification, this is believed to pass through activa-
tion (phosphorylation) of ERK1 and ERK2, which can be
achieved by both BMP2 and the phosphate transporter
PiT-1. Though PXE tissues showed overexpression of
pERK1/2, expression levels of PiT-1 were normal. Together
with the normal phosphate levels in PXE patients, this ex-
cludes PiT-1 mediated ERK1/2 activation in PXE, but ra-
ther points towards an effect of BMP2. In epithelial cells,
ERK1/2 activation has been shown to be precipitated by
calcium influx [60]. It can thus not be excluded that the
increased calcium in cultured PXE fibroblast, seen on
Alizarin Red labelling, may serve as a positive feedback
loop for ERK1/2 activity [61,62].
Figure 9 (See legend on next page.)
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Figure 9 Immunohistochemical staining results for Caspase 3 and Caspase 8. Upper panel: Staining is performed on whisker and eye
sections from the Abcc6 knockout mouse (A-D, ×10) and human skin (E, F, ×20). Alizarin Red stains was used to localize mineralization (A, C).
Positive staining for Caspase 3 is obtained on murine whiskers and eye (B, asterisk; D, arrow), co-localizing with ectopic mineralization. In human
PXE dermis, Caspase 3 stains positive in the middermis (E, asterisk), while no staining is noted in controls (F). Scale bar = 100 μm. Lower panel:
Fluorescent immunohistochemistry for Caspase 8 and RUNX2 confirms co-localisation in PXE skin (J, white arrow). DAPI nuclear staining (G).
Merged RUNX2-DAPI image ((H, green fluorescence indicates RUNX2 staining, arrow) and merged Caspase 8-DAPI image (I, red fluorescence
indicates Caspase-8 staining, arrow). (n = 5 each). Scale bar = 20 μm.
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http://www.ojrd.com/content/9/1/66A second downstream mediator of BMP2 is MSX2, a
transcription factor which promotes cardiovascular cal-
cification by stimulating canonical Wnt signalling [31].
MSX2 induces nuclear stabilization of β-catenin result-
ing in a positive feedback of MSX2 expression and in
the activation of TCF-1/LEF-1 transcription [31]. The
upregulation of MSX2 and TCF-1/LEF-1 in PXE cells
demonstrates involvement of MSX2-Wnt signalling in
PXE. The diminished expression of DLX5, an important
negative regulator of MSX2-Wnt signalling, may also
contribute to MSX2 overexpression in PXE. Suppression
of DLX5 is well-known in several embryological mecha-
nisms. Though the precise mechanisms are ill-defined,
the role of transcription factors and epigenetic factors
such as microRNAs has been documented and may be
tissue-specific [63,64]. The clinical importance of Wnt
signalling has been shown for many disorders, where
Wnt effectors can serve as susceptibility genes or modi-
fiers [65]. The involvement of canonical Wnt signalling
in PXE should thus encourage us to study Wnt-related
pathways further.
The role and regulation of the third mediator of
BMP2, OSX, is incompletely understood. OSX is a mem-
ber of the Sp1 transcription factor family and plays an
essential role in bone formation and osteoblastogenesis
[66]. In soft tissue mineralization, OSX has been attrib-
uted an important role in the transdifferentiation of
smooth muscle cells into osteoblasts. Initially thought to
function downstream of RUNX2, OSX expression inFigure 10 qPCR result for mediators of apoptosis reported in vascula
expression shows a significant downregulation of BCL-2 and upregulation
5 for patients and controls respectively). *p < 0.05.osteoblasts was shown to be regulated by RUNX2-
dependent and -independent mechanisms which are not
necessarily simultaneously active [67]. Several factors
such as OC, PTH, SP1 and DLX5 can influence OSX ac-
tivity [68]. In PXE fibroblasts, OSX is not upregulated.
The lack of OSX overexpression might explain why PXE
fibroblasts, though they show an osteoblast gene expres-
sion profile, do not transform morphologically into
osteoblasts.
The different TGFβ ligands (TGFβ-1, TGFβ-2, TGFβ-
3) form a second group of TGFβ superfamily members
which are implicated in vascular calcification [48]. TGFβ
signalling in the vasculature is predominantly dependent
on the activation of any of two type 1 receptors, Alk5
(TGFBR1) and Alk1 (ACVRL1), and signal transduction
through activation of SMADs [69,70]. Among TGFβ li-
gands, TGFβ-1 is most frequently involved and promotes
aortic smooth muscle cell calcification in culture, in-
creases nodule formation in calcifying vascular cells
in vitro, and is present in calcified aortic cusps [71-73].
Though TGFβ has already been suggested to be involved
in PXE by Jiang et al., who reported that ABCC6 pro-
moter activity can be modulated by several cytokines in-
cluding TGFβ [74], it was somewhat unexpected to find
only overexpression of TGFβ-2 in PXE fibroblasts, while
expression of the other ligands (TGFβ-1 and TGFβ-3)
remained the same as in controls. TGFβ-2 is expressed
in the VSMCs of calcified arteriosclerotic arteries, in-
duces chondrogenic differentiation of mesenchymal stemr soft tissue mineralization (PiT-1, P21, BCL-2 and GAS6). Relative
of GAS6 in human PXE fibroblasts compared to control cells. (n = 8 and
Figure 11 qPCR results for genes involved in UPR dependent ER-stress and apoptosis including CHOP, BIP, XBP1, IRE1, ATF4, ATF6,
GAD34, JNK, XBP-S. Relative expression is shown in human PXE fibroblasts and control cells. No significant change in expression of any gene is
observed. (n = 8 and 5 for patients and controls respectively). *p < 0.05.
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http://www.ojrd.com/content/9/1/66cells and induces calcifying activity in the human tra-
becular meshwork cells [75], but nearly always together
with and less than TGFβ-1. Solitary TGFβ-2 overexpression
seems to be unique in soft tissue mineralization diseases.
Interestingly, isolated TGFβ-2 overexpression was found in
models of choroidal neovascularisation, a complication
often seen in PXE patients [76]. Further, the observed in-
creased level of MMP2 and MMP9 in PXE serum may also
reflect TGFβ-2 activity, as it has a pivotal role in activating
both metalloproteases [77-79]. Involvement of TGFβ-2 in
PXE was further confirmed by increased expression of itsFigure 12 Immunohistochemical staining results for pERK1/2 (×10). S
(A-C) and PXE skin tissues (D-F). Alizarin Red stains was used to localize m
murine whisker (B, arrow) and PXE skin (E, asterisk), co-localizing with mine
staining could represent the active mineralization process where pERK1/2 e
whisker (C) and control skin tissue (F). (n = 5 each). Scale bar = 100 μm.downstream effectors pSMAD2, pSMAD4 and CTGF
(Connective Tissue Growth factor) [80,81]. CTGF is con-
sidered a mediator of TGFβ signalling in fibroblasts. In
adult skin, CTGF is normally not expressed, unless induced
for example during wound healing. The absence of CTGF
labelling in the murine whiskers and eye may reflect a
physio-immunological difference in between human and
mice, rather than an actual difference in murine and human
PXE pathogenesis.
Besides BMP2/TGFβ and Wnt signalling, also oxida-
tive stress, endoplasmic reticulum stress and apoptosistaining is performed on whisker from the Abcc6 knockout mouse
ineralization (A and D). Positive staining for pERK1/2 is obtained on
ralization. The pERK1/2 staining being broader than the mineralization
xpression precedes calcification. No staining is noted in control
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http://www.ojrd.com/content/9/1/66can play a role in soft tissue calcification. PXE fibroblasts
are well known to suffer mild chronic oxidative stress
[82]. For all signalling pathways which are perturbed in
PXE, a potential influence of reactive oxygen species
(ROS) has been documented. There is some indication
that BMP signalling may be mediated through ROS
function and signalling [83]. ROS are able to induce both
BMP2-RUNX2 signalling and MSX2-Wnt signalling,
thus causing soft tissue calcification [84-86]. ROS-
induced calcification was found to be retracted in
RUNX2 knock-down cells, suggesting it to be RUNX2
dependent [87]. However, ROS has also been docu-
mented to influence those mediators which were normal
in PXE, such as BMP4 [88]. This duality makes it less
convincing that the contribution of ROS is a truly sig-
nificant in PXE, though this remains difficult to assess.
The mechanisms of ER stress in vascular calcification
include activation of the unfolded protein response
(UPR), through unfolded protein sensors such as IRE1.Figure 13 Preliminary cell model of ECM calcification in PXE. PXE fibro
including BMP2-SMADs-RUNX2, TGFβ-2-SMADs-CTGF, MSX2-Wnt and pERK
through RUNX2 and BCL-2. Besides the ECM mineralization, some of the pe
related to neovascularisation, a common process in the complicated PXE reUPR aims to restore normal ER function or, if not pos-
sible, aims towards apoptosis [89]. It involves a complex
cascade of chaperone proteins (GRP78 and GRP94), acti-
vation of caspases, and induction of RUNX2 and OC via
transcription factors ATF4 and XBP1s [90-93]. The
presence of abundant and extremely dilated cisternae of
the ER has been reported in PXE fibroblasts, as well as
slightly modified GRP78 proteins [94-96]. Though this
was suggestive for an involvement of ER stress, no sig-
nificant change in expression level of ER stress markers
previously implicated in vascular calcification (CHOP,
IRE1, XBP1, ATF4 and ATF6) was noted in PXE fibroblast
[97]. Based on this, we would conclude that ER stress does
not play a major role in the PXE pathogenesis.
It is well known from calcified vasculopathies that an in-
creased rate of apoptosis and apoptotic bodies function as a
nidus for calcification [28]. Recent data have suggested that
BMP2 and RUNX2 are pro-apoptotic factors [98,99]. The
involved mechanisms depend on the cell-type. In soft tissueblasts reveal perturbation of a specific set of signalling pathways
signalling. Apoptosis seems to be involved in PXE mineralization
rturbed signalling molecules, such as RUNX2 and TGFβ-2 can be
tinopathy.
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of cell-cycle arrest marker P21 and direct activation of Cas-
pase 3, 8 and 9 [53,98,100]. In addition, increased levels of
P and Ca2+, and oxidative stress also have a major role in
apoptosis mediated soft tissue calcification [86,101]. On
TUNEL staining for in situ cell death, PXE fibroblasts re-
veal a marked increase of apoptosis compared to controls.
Apoptosis has never been reported in PXE, though the rela-
tion between Abcc6 deficiency and cell death has been re-
ported in Abcc6 deficient mice with increased cardiac
apoptosis and upregulation of BMP responsive transcrip-
tion factors pSmad1/5/8 in the heart [37]. Of the three
major mechanisms, PXE fibroblasts were noted to show a
decreased BCL-2 expression and activation of Caspase 3
and Caspase 8. However the activity of P21 was not dif-
ferent in PXE fibroblasts compared to controls. Similar
pro-apoptotic effects downstream of BMP2 were noted in
pulmonary vascular smooth muscle cells [102,103]. There,
BMP2 had the ability to increase caspase activity either dir-
ectly or via RUNX2 [104,105]. The observation in PXE tis-
sues that co-localization of Caspase 3 in mineralized area,
and co-localization of RUNX2 with Caspase 8, suggested
an important role for RUNX2 in PXE-related apoptosis.
siRNA mediated silencing of RUNX2 demonstrated a de-
crease of apoptosis after 24 and 48 hours, though results
were variable and apoptosis was still present despite
RUNX2 downregulation. Though we did not achieve a
complete siRNA-induced knockdown of RUNX2, this is in
favour of a dual BMP2 and BMP2-RUNX2 effect as in
other soft tissue cells. Whether other pro-apoptotic mecha-
nisms are simultaneously at work in PXE cells remains to
be determined.
Of interest is the observation that TUNEL staining in
PXE fibroblasts is primarily present in the cytoplasm in-
stead of the nucleus. This might be due to rapid degrad-
ation of the nuclear membrane due to cell death, though it
has also been thought to reflect mitochondrial DNA dam-
age [106,107]. As the positive control cells showed nuclear
TUNEL staining, we consider it unlikely that the labelling
in PXE fibroblasts is an artifact. This may further corrobor-
ate the involvement of mitochondria in the PXE patho-
physiology, which was already suggested by previously
reported ultra-structural and functional abnormalities of
the mitochondria in PXE as well as the recent report of the
presence of the ABCC6 transporter in the mitochondria-
associated membranes [108,109]. However, further study is
needed to assess to which extent mitochondrial dysfunction
is implicated in the PXE pathogenesis.
Conclusions
Our study shows that we cannot simply extrapolate know-
ledge on cell signalling in vascular soft tissue calcification
to a multisystem ectopic mineralisation disease such as
PXE. Contrary, we demonstrate a specific set of perturbedsignalling pathways in PXE patients and the knock-out
mouse model. Based on our findings and literature reports,
we propose a preliminary cell model of ECM calcification
in PXE (Figure 13). In the intricating web of calcification in-
hibitor and propagator signalling, this presents a starting
point to further unravel the complex cellular signalling in
PXE. Besides their relevance for elastic fibre mineralization,
the pathways that we found disturbed may have a relevance
for other features of the PXE phenotype, such as neovascu-
larisation. PXE patients often suffer subretinal neovasculari-
sation and haemorrhaging as a complication of the PXE
retinopathy [110,111]. VEGF-A, a potent mediator of
angiogenesis, is assumed to play a role in this neo-
angiogenesis, as treatment of PXE patients with anti-VEGF
injections has been very successful [112]. However, the
mechanism behind VEGF-A involvement has not yet been
uncovered. Runx2 has been described to induce overex-
pression of Vegf-A and the upregulation of Runx2 in
Bruch’s membrane of the PXE KO mouse model, may con-
tribute to the presence of VEGF-A in the eye [52]. Also, the
TGFβ-2 predominance in experimental models of choroidal
neovascularization may provide further insights in the PXE
retinopathy [71]. These results may also have implications
for future therapies for this as yet intractable disease. Cura-
tive treatments targeting just one of the biochemical abnor-
malities in PXE, being it e.g. vitamin K deficiency or
oxidative stress, might not be sufficient because of their
synergistic effect [69,70,113]. Conversely, a more central
component such as RUNX2 might provide a powerful tar-
get to influence these different mechanisms, as well as the
BMP2 receptor. Indeed, several small-molecule inhibitors
of BMP receptors have been developed and mouse models
of ectopic mineralization diseases such as Fibrodysplasia
Ossificans Progressiva, where BMP pathways are deregu-
lated, have already been successfully treated with these
compounds [114,115].Additional files
Additional file 1: List of primers used in qPCR experiments.
Additional file 2: Rate of apoptosis (%) in PXE fibroblasts compared
to controls. PXE fibroblasts showed 3× more apoptosis compared to
controls. (n = 8 and 5 for patients and controls respectively).
Additional file 3: Magnification of TUNEL staining in native PXE
fibroblasts (×40). Positive labelling in the cytoplasm of the cells is
arrowed. Scale bar = 50 μm.
Additional file 4: Relative expression of RUNX2 in PXE fibroblasts
transfected with anti-RUNX2 siRNA after 24, 48 and 72 hours. siRNA
silencing causes a downregulation of RUNX2 expression of 65% at
24 hours, 54% at 48 hours and 28% at 72 hours. (n = 6 each).
Additional file 5: Quantification of the effect of RUNX2 knockdown
on apoptosis in PXE fibroblasts (n = 2 cultures). Results are shown
after 24, 48 and 72 hours respectively and demonstrate a 13 to 20%
reduction of apoptosis, though results differ between different cell lines.
After 72 hours, no reducing effect of siRNA silencing of RUNX2 on
apoptosis can be seen anymore.
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